1h Free Analyst Time
The publisher has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by $ 3.48 bn during 2021-2025, progressing at a CAGR of 14.05% during the forecast period. The report on the biosimilar monoclonal antibodies (mAbs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases and increase in the number of expiring patents of blockbuster mAbs.
The biosimilar monoclonal antibodies (mAbs) market analysis includes the application segment and geographic landscape.
The biosimilar monoclonal antibodies (mAbs) market is segmented as below:
By Application
- Cancer
- Non-cancer
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the growing approval for biosimilar mAbs as one of the prime reasons driving the biosimilar monoclonal antibodies (mAbs) market growth during the next few years.
The report on biosimilar monoclonal antibodies (mAbs) market covers the following areas:
- Biosimilar monoclonal antibodies (mAbs) market sizing
- Biosimilar monoclonal antibodies (mAbs) market forecast
- Biosimilar monoclonal antibodies (mAbs) market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biosimilar monoclonal antibodies (mAbs) market vendors that include Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Celltrion Co. Ltd., Novartis AG, Coherus Biosciences Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, and Pfizer Inc. Also, the biosimilar monoclonal antibodies (mAbs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Application
- Market segments
- Comparison by Application
- Cancer - Market size and forecast 2020-2025
- Non-cancer - Market size and forecast 2020-2025
- Market opportunity by Application
Customer landscape
- Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Amgen Inc.
- BIOCAD
- Biocon Ltd.
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Celltrion Co. Ltd.
- Coherus Biosciences Inc.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Application - Market share 2020-2025 (%)
- Comparison by Application
- Cancer - Market size and forecast 2020-2025 ($ million)
- Cancer - Year-over-year growth 2020-2025 (%)
- Non-cancer - Market size and forecast 2020-2025 ($ million)
- Non-cancer - Year-over-year growth 2020-2025 (%)
- Market opportunity by Application
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Amgen Inc. - Overview
- Amgen Inc. - Business segments
- Amgen Inc. - Key offerings
- Amgen Inc. - Key customers
- Amgen Inc. - Segment focus
- BIOCAD - Overview
- BIOCAD - Product and service
- BIOCAD - Key offerings
- BIOCAD - Key customers
- BIOCAD - Segment focus
- Biocon Ltd. - Overview
- Biocon Ltd. - Business segments
- Biocon Ltd. - Key offerings
- Biocon Ltd. - Key customers
- Biocon Ltd. - Segment focus
- BioXpress Therapeutics SA - Overview
- BioXpress Therapeutics SA - Product and service
- BioXpress Therapeutics SA - Key offerings
- BioXpress Therapeutics SA - Key customers
- BioXpress Therapeutics SA - Segment focus
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Business segments
- Boehringer Ingelheim International GmbH - Key offerings
- Boehringer Ingelheim International GmbH - Key customers
- Boehringer Ingelheim International GmbH - Segment focus
- Celltrion Co. Ltd. - Overview
- Celltrion Co. Ltd. - Product and service
- Celltrion Co. Ltd. - Key offerings
- Celltrion Co. Ltd. - Key customers
- Celltrion Co. Ltd. - Segment focus
- Coherus Biosciences Inc. - Overview
- Coherus Biosciences Inc. - Business segments
- Coherus Biosciences Inc. - Key offerings
- Coherus Biosciences Inc. - Key customers
- Coherus Biosciences Inc. - Segment focus
- Intas Pharmaceuticals Ltd. - Overview
- Intas Pharmaceuticals Ltd. - Product and service
- Intas Pharmaceuticals Ltd. - Key offerings
- Intas Pharmaceuticals Ltd. - Key customers
- Intas Pharmaceuticals Ltd. - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global biosimilar monoclonal antibodies (mAbs) market: Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Celltrion Co. Ltd., Novartis AG, Coherus Biosciences Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, and Pfizer Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is growing approval for biosimilar mAbs.`
According to the report, one of the major drivers for this market is the increasing prevalence of chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- BIOCAD
- Biocon Ltd.
- BioXpress Therapeutics SA
- Celltrion Co. Ltd.
- Novartis AG
- Coherus Biosciences Inc.
- Intas Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
